Cancer therapy-related cardiac dysfunction

1. SGLT2 inhibitors have no effect on cancer therapy-related cardiac dysfunction in humans (HR 0.99, 95% CI 0.80–1.22).

   “the incidence of CTRCD was similar between the two groups (13.5% vs 13.6%; HR 0.99, 95% CI 0.80–1.22; p = 0.91).”

   Humansin T2DM patients undergoing cardiotoxic cancer therapy1 yearn = 2,656

   Real-World Data Show No Preventive Effect of SGLT2 Inhibitors on Cardiac Dysfunction from Cancer Therapy in T2DM Patients

   AHA Scientific Sessions 2025 abstract·3 Nov 2025

More on SGLT2 inhibitors